Day: November 14, 2024

VANCOUVER, British Columbia, Nov. 14, 2024 (GLOBE NEWSWIRE) — Refined Energy Corp. (CSE: RUU; OTC: RFMCF; FRA: CWA0) (the “Company”) announces effective November 15, 2024, the Company will extend the expiry date of an aggregate of 2,598,335 outstanding common share purchase warrants (the “Warrants”) by one year, such that the Warrants, which had been scheduled to expire on November 29, 2024, will now have an expiry date of November 29, 2025 (the “Warrant Amendment”). All other terms of the Warrants will remain unchanged. The Warrant Amendment remains subject to acceptance by the Canadian Securities Exchange. The Warrants were originally issued on November 29, 2021, pursuant to a private placement of units at of the Company (each, a “Unit”) at a price of $0.12 per Unit. Each Unit consisted of one common share of the Company (“Share”)...

BALTIMORE, Nov. 14, 2024 (GLOBE NEWSWIRE) — Adams Natural Resources Fund, Inc. (NYSE: PEO) declared today a year-end distribution of $1.03 per share. The total distributions by the Fund for 2024 will be $1.77, including the distributions totaling $0.74 per share made in 2024 prior to today’s announcement. The annual distribution rate represented by these distributions is 6.7%. The Fund’s estimated sources for the distribution to be paid on December 19, 2024 and for all distributions declared in 2024 to date are as follows:  Distribution per Share Net Investment Income Net Realized Short-Term Gains Net Realized Long-Term Gains Return of CapitalDecember 19, 2024 $1.03 $0.14 (14%) $0.00 (0%) $0.89 (86%) $0.00 (0%)YTD 2024 $1.77 $0.65 (37%) $0.00 (0%) $1.12 (63%) $0.00 (0%)Fund Performance and Distribution Rate...

VANCOUVER, British Columbia, Nov. 14, 2024 (GLOBE NEWSWIRE) — Avricore Health Inc. (TSX-V: AVCR) (“Avricore” or the “Company”), a leader in pharmacy-based point-of-care testing solutions, today announces a strategic shift to increase its focus on the rapidly expanding UK healthcare market and begin concluding its Canadian pharmacy partnership with Shoppers Drug Mart. This shift in market development builds on the UCL Partners announcement of its rapid cholesterol initiative in community pharmacies in North East London. Key Business Update:Shoppers Drug Mart existing program to wind down over a multi-month transition period, ending March 30, 2025 Continuing growth strategy execution with Canadian pharmacy customers such as Rexall throughout 2025 Advancing ongoing business development initiatives and discussions...

LA JOLLA, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) — MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), announces that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for a pending patent application for MN-001 (Tipelukast) to cover “Method to Decrease Triglyceride Synthesis in a Liver of a Subject.” The allowed claims cover a groundbreaking method for decreasing triglyceride synthesis in the liver by administering MN-001 (Tipelukast) or its metabolite or pharmaceutically acceptable salt. This method is particularly beneficial for subjects diagnosed with insulin resistance, pre-diabetes, or diabetes. Once issued, this patent is expected to expire no earlier than May...

NORWELL, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) — DIH Holding US, Inc. (“DIH”)(NASDAQ:DHAI), a global provider of advanced robotic devices used in physical rehabilitation, which incorporates visual stimulation in an interactive manner to enable clinical research and intensive functional rehabilitation and training in patients with walking impairments, reduced balance and/or impaired arm and hand functions, today announced financial results for the second fiscal quarter ended September 30, 2024, and a restatement of the financial results for the first fiscal quarter ended June 30, 2024, to account for the timing of revenue and associated cost of sales recognition for two devices sold in late June 2024. Recent HighlightsRevenue of $18.2 million for the quarter ended September 30, 2024, representing growth of 39% over...

Company successfully listed on Nasdaq under the symbol “AIFF” Partnered with multiple neuroscience pharmaceutical companies, including Bright Minds Bioscience, and neurologists to advance Company’s dual go-to-market strategy TORONTO, Nov. 14, 2024 (GLOBE NEWSWIRE) — Firefly Neuroscience, Inc. (“Firefly,” “we,” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders, today announced its financial results for the third quarter ended September 30, 2024, and provided a stockholder update. Firefly is dedicated to improving outcomes for people suffering with brain health illnesses by bringing objective measurement of brain activity to the front lines of healthcare. The Company’s go-to-market strategies...